EP0929308B1 - Pharmaceutical composition containing an embryonic extract as an active substance and relative preparation process - Google Patents
Pharmaceutical composition containing an embryonic extract as an active substance and relative preparation process Download PDFInfo
- Publication number
- EP0929308B1 EP0929308B1 EP97928188A EP97928188A EP0929308B1 EP 0929308 B1 EP0929308 B1 EP 0929308B1 EP 97928188 A EP97928188 A EP 97928188A EP 97928188 A EP97928188 A EP 97928188A EP 0929308 B1 EP0929308 B1 EP 0929308B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- embryonic
- stage
- embryos
- embryonic development
- antioncogene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- organogenesis period intervene, in fact, some regulating substances which prevent the unlimited multiplication of the cells, typical of the cancer development, characterizing them in a specific sense.
- mice wherein cells of Lewis pulmonary carcinoma had been subcutaneously implanted The effect has been determined in mice wherein cells of Lewis pulmonary carcinoma had been subcutaneously implanted.
- tumour represents a complex problem to the genesis thereof different factors contribute: oncogenes, lack of oncosuppressor genes, autocrine growth factors etc.
- oncogenes a complex problem to the genesis thereof different factors contribute: oncogenes, lack of oncosuppressor genes, autocrine growth factors etc.
- a situation of such complexity can not be faced with therapeutic strategies based on the use of few substances and therefore the problem remaining open is to search for differentiated treatments dependent upon the various kinds of tumours.
- extracts of embryos taken in specific stages of the embryonic development are effective in the treatment of the tumours and the other pathologies controlled by the p53 antioncogene and that said specific stages change dependent upon the species of origin of the extracts.
- the present invention refers to pharmaceutical compositions containing as active substances extracts of embryos taken in specific stages of the embryonic development in mixture with pharmacologically acceptable diluents or excipients, suitable for the treatment of the tumours and the other pathologies controlled by the p53 antioncogene.
- the present invention further refers to the process for the preparation of said extracts and said compositions.
- Embryos suitable for the use according to the present invention are taken from the species comprising brachydanio rerio, trout, and drosophila.
- the embryos are taken at specific stages of the embryonic development, different for the different pathologies and different for different species.
- the primitive tumour of the liver is successfully treated with trout embryonic extracts at the development stage of 20 somites; the glioblastoma multiforme is successfully treated with trout embryonic extracts at the development stage of 5 and 20 somites and with brachydanio rerio embryos at the medioblastula-gastrula stage; the ovarioncus is successfully treated with brachydanio rerio embryonic extracts at the development stage of medioblastula-gastrula; the Lewis tumour is successfully treated with drosophila embryonic extracts at the blastoderma stage.
- the preparation of the extracts is carried out in a different way according to the kind of embryo and to the embryogenesis map elaborated for the species under examination, acting according to the methods described in detail in the below reported examples.
- the preparation of the extracts is carried out by the following steps:
- the sonication time of the step a) is preferally ranging from 1 to 4 hours.
- the solvent used in the step c) consists of a mixture of glycerin and a 30% v/v ethyl alcohol aqueous solution, in a 85:15 v/v ratio.
- the ratio by weight between said solvent and said embryos is preferably ranging from 20:1 to 2:1.
- the stirring of the step d) is preferably carried out at room temperature, as the other operations too, for a time from 2 hours to 15 hours.
- the extracts according to the present invention have been used in an in vitro experimentation in order to determine their anti-tumour efficacy.
- the obtained results have been the following ones: slowing of the growth curve of the cancer cells treated with the extracts and activation of the p53 antioncogene.
- the embryonic extracts according to the present invention may be successfully used in the preparation of compositions suitable to the treatment of the pathologies controlled by the p53 antioncogene which, beside tumorous pathologies, include several autoimmune diseases such as the autoimmune thyroidites, the lupus erythematosus, the rheumatoid arthritis, genetic pathologies such as the pigmentous scleroderma and the psoriasis, and viral pathologies such as the sclerose en plaques, the AIDS etc.
- autoimmune diseases such as the autoimmune thyroidites, the lupus erythematosus, the rheumatoid arthritis, genetic pathologies such as the pigmentous scleroderma and the psoriasis, and viral pathologies such as the sclerose en plaques, the AIDS etc.
- compositions are formulated with pharmacologically acceptable diluents and excipients, in solid, semisolid or liquid form depending on the kind of administration and pathology.
- compositions are prepared in the form of liquid solutions for parenteral, topical, oral and spray use. eye-drops. semisolid preparations such as creams, gels, ointments and pastes, solid preparations such as powders and freeze-dried products, impregnated gauzes, urethral sticks, oral emulsions and sprays, syrups, simple and coated granulates, simple and coated tablets, soft and hard, simple and modified release capsules, suppositories, vaginal globuli and suppositories and plasters.
- compositions according to the invention may be used for the human therapy of the pathologies controlled by the p53 antioncogene with a posology which provides for the administration of a quantity from 10 ⁇ g to 200 mg of embryonic extract per day.
- the spawn are taken by mild ventral squeezing, after a light narcosis of the fish.
- the spawn are then rinsed many times with bidistilled water and finally washed with 60% ethyl alcohol.
- a solvent is prepared consisting of glycerin and 30% ethyl alcohol, in a 85:15 v/v ratio. The solvent is added to a weight of the mixture equal to 5 kg.
- the mixture is treated with a vacuum turbodiffuser, alternating settling periods, for about 12 hours.
- the mixture is filtered by 90 micrometers filter cartridges, then it is filtered by 10 micrometers cartridges in order to remove the spawn shells and the fat.
- the solution about 5 kg, is diluted to 50 kg with ethyl alcohol.
- the solution is filtered which appears clear with 5 micrometers filter cartridges.
- Such solution forms the liquid formulation for the oral administration. According to the desired dosage it may be further diluted with 30% ethyl alcohol.
- the preferred concentration is 0.1 embryo/ml.
- the taking has been carried out by the previously described method, that is the spawn have been taken at the moment of medioblastula-gastrula embryonic growth by mild ventral squeezing, after light narcosis of the fish.
- the extract has been obtained acting as the method described in the Example 1.
- 50 microliters of the so obtained extract have been inoculated in a culture of 3.5 x 10 5 cancer cells of glioblastoma multiforme in comparison with an untreated culture of cancer cells of glioblastoma multiforme.
- the obtained results have been the following ones: unsuccessful activation of the p53 antioncogene in the treated cancer cells as in the control ones.
- the obtained results have been the following ones: unsuccessful activation of the p53 antioncogene in the treated cancer cells as in the control ones.
- the extract prepared as in the Example 1, but consisting of trout embryos at the medioblastula-gastrula stage has been inoculated in cultures of cancer cells of glioblastoma multiforme in comparison with untreated cultures of cancer cells of glioblastoma multiforme, as in the Example 1.
- the obtained results are the following ones: unsuccessful activation of the p53 antioncogene in the treated cancer cells as in the control ones.
- the primary tumour growth curve and the survival times have been estimated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
Claims (6)
- Pharmaceutical composition suitable for the treatment of the tumours and the pathologies controlled by the p53 antioncogene, containing as active substance an embryonic extract taken in specific stages of the embryonic development depending on the specific tumour and the specific pathology and dependent upon the species of origin of the extract, characterized in that said embryonic extract is taken from the species comprising trout in stages of embryonic development of 5 and 20 somites, brachydanio rerio in stage of embryonic development of medioblastula-gastrula and drosophila in stage of embryonic development of blastoderma.
- Composition as claimed in claim 1, characterized in that said tumours and said pathologies controlled by the p53 antioncogene include the primitive tumour of the liver, the glioblastoma multiforme, the ovarioncus, the Lewis tumour, the autoimmune thyroidites, the lupus erythematosus, the rheumatoid arthritis, the pigmentous scleroderma, the psoriasis, the sclerose en plaque and the AIDS.
- Process for the preparation of compositions as defined in claim 1, comprising:a) taking embryos at a stage specific of the embryonic development;b) treating said embryos with several sonication cycles;c) adding a solvent;d) stirring the mixture obtained in the step c) by a turbodiffuser;e) filtering the mixture first by 90 micrometers filters and then with 5-10 micrometers filters, characterized in that said specific stage of the embryonic development of step a) is selected from the stage of mediobastula-gastrula for brachydanio rerio, 5 somites and 20 somites for trout and blastoderma for drosophila, and said solvent of step c) consists of a mixture of glycerin and a 30% v/v ethyl alcohol aqueous solution, in a 85/15 v/v ratio.
- Process as claimed in claim 3, characterized in that the ratio by weight between said solvent and said embryos ranges from 20:1 to 2:1.
- Process as claimed in claim 3, characterized in that the stirring of the step d) is carried out at room temperature for a time from 2 hours to 15 hours.
- Use of embryonic extracts as defined in claim 1 for the preparation of compositions for the treatment of the tumours and the pathologies controlled by the p53 antioncogene, in mixture with pharmacologically acceptable diluents and excipients in solid, semisolid or liquid form, for the administration by parenteral, oral or topical way.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI961945 | 1996-09-20 | ||
IT96MI001945A IT1284571B1 (en) | 1996-09-20 | 1996-09-20 | ANTI-CANCER COMPOSITION CONTAINING AN EMBRYONAL OR PREGNANT UTERUS EXTRACT AS THE ACTIVE SUBSTANCE AND RELATED PROCEDURE FOR PREPARATION |
PCT/EP1997/003071 WO1998011905A1 (en) | 1996-09-20 | 1997-06-12 | Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0929308A1 EP0929308A1 (en) | 1999-07-21 |
EP0929308B1 true EP0929308B1 (en) | 2002-08-21 |
Family
ID=11374912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97928188A Expired - Lifetime EP0929308B1 (en) | 1996-09-20 | 1997-06-12 | Pharmaceutical composition containing an embryonic extract as an active substance and relative preparation process |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0929308B1 (en) |
AT (1) | ATE222499T1 (en) |
AU (1) | AU3258097A (en) |
DE (1) | DE69714856T2 (en) |
ES (1) | ES2181004T3 (en) |
IT (1) | IT1284571B1 (en) |
WO (1) | WO1998011905A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999654B2 (en) | 2012-09-19 | 2018-06-19 | Sc Hipocrate 2002 Serv Srl | Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA003301B1 (en) * | 2000-04-28 | 2003-04-24 | Научно-Производственное Республиканское Унитарное Предприятие "Диалек" | Method for preparing a medicament from brain tissue of animal embryo and pharmaceutical composition based thereon |
WO2003063883A1 (en) * | 2002-01-30 | 2003-08-07 | Airumiyan, Asmik Vardgesovna | Mkrtachian embryonal antitumoral modulator, method for the production and use thereof |
ITMI20021362A1 (en) * | 2002-06-20 | 2003-12-22 | Biava Pier Mario | USE OF AN ANIMAL EMBRYON EXTRACT AS A NOURISHING SUBSTANCE AND DIETARY-NUTRACEUTICAL SUPPLEMENT |
ITMI20051572A1 (en) * | 2005-08-12 | 2007-02-13 | Alberto Astaldi | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE SUBSTANCE A PROTEIN FRACTION EXTRACTED FROM EMBRYOS OF OVIPARIANS IN THE PERIOD OF CELLULAR DIFFERENTIATION AND RELATIVE PREPARATION PROCESS |
ES2337537B8 (en) * | 2008-03-19 | 2011-08-01 | Joan Cunill Aixela | PREPARED FOOD AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYO EXTRACT AND ITS RESPECTIVE USES. |
WO2009146750A1 (en) * | 2008-06-05 | 2009-12-10 | Montco Cancer Research B.V. | Anti-cancer immune-modulating agent |
IT1400147B1 (en) * | 2010-03-16 | 2013-05-17 | Univ Roma | USE OF A MORPHOGENIC FIELD FOR THE REVERSION OF THE PHENOTYPE OF TUMOR CELLS |
US9750773B2 (en) * | 2014-08-07 | 2017-09-05 | Michele BIAVA | Factors extracted from fish embryos and use of mixtures thereof in the control of stem cell multiplication and differentiation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2451193A1 (en) * | 1979-03-13 | 1980-10-10 | Brunel Henri | Total embryonic complex for treatment of cancer - and as anti-reject agent in organic grafts and transplants, comprises a colloidal suspension of embryo |
DE4400640A1 (en) * | 1994-01-12 | 1995-07-13 | Eftag Entstaubung Foerdertech | Diagnosis and treatment of malignant tumours |
-
1996
- 1996-09-20 IT IT96MI001945A patent/IT1284571B1/en active IP Right Grant
-
1997
- 1997-06-12 DE DE69714856T patent/DE69714856T2/en not_active Expired - Lifetime
- 1997-06-12 ES ES97928188T patent/ES2181004T3/en not_active Expired - Lifetime
- 1997-06-12 AT AT97928188T patent/ATE222499T1/en not_active IP Right Cessation
- 1997-06-12 WO PCT/EP1997/003071 patent/WO1998011905A1/en active IP Right Grant
- 1997-06-12 AU AU32580/97A patent/AU3258097A/en not_active Abandoned
- 1997-06-12 EP EP97928188A patent/EP0929308B1/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999654B2 (en) | 2012-09-19 | 2018-06-19 | Sc Hipocrate 2002 Serv Srl | Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment |
Also Published As
Publication number | Publication date |
---|---|
DE69714856D1 (en) | 2002-09-26 |
ATE222499T1 (en) | 2002-09-15 |
IT1284571B1 (en) | 1998-05-21 |
ES2181004T3 (en) | 2003-02-16 |
WO1998011905A1 (en) | 1998-03-26 |
ITMI961945A1 (en) | 1998-03-20 |
DE69714856T2 (en) | 2003-05-22 |
EP0929308A1 (en) | 1999-07-21 |
AU3258097A (en) | 1998-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3689909T2 (en) | Use of a substance containing GHL-Cu for the manufacture of a medicament for wounds. | |
KR20150020113A (en) | Mesenchymal stem cells treated mTOR/STAT3 signaling inhibitor having immuno-modulating activity and cell therapeutic agent for preventing or treating immune disease | |
EP0929308B1 (en) | Pharmaceutical composition containing an embryonic extract as an active substance and relative preparation process | |
DE69213943T2 (en) | SHORT-TIME STIMULATION OF LYMPHOCYTES WITH ANTI-CD3 ANTIBODIES TO INCREASE YOUR IN VIVO ACTIVITY | |
JP2002526407A (en) | Fulvic acid and its use in treating various conditions | |
WO2003039444A2 (en) | Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases | |
van der Spuy, S., Levy, DW & Levin | Cimetidine in the treatment of herpesvirus infections | |
CN101491533B (en) | Use of baicalin in preparing medicine | |
KR101734093B1 (en) | A pharmaceutical composition for preventing and treating inflammatory disease containing the purified bee venom which was reduced allergen, as a active ingredient | |
JPH09503206A (en) | Composition for preventing and treating virus-induced tumor | |
EP2310023A2 (en) | Composition useful for the prevention or reduction of the progression of prostate cancer | |
JPH08143462A (en) | Immunostimulating agent and antitumor agent | |
DE3539775C2 (en) | New lymphokine, antibodies specific to this lymphokine, process for their preparation and their use | |
JP3856680B2 (en) | Carcinogenic promoter inhibitor and composition containing the same | |
CN116685591A (en) | Treatment of dermatological disorders | |
JP2001518107A (en) | Use of proteins extractable from animal organs for preparing a medicament for the treatment of a pathological condition characterized by overproduction of tumor necrosis factor (TNF) | |
KR960011231B1 (en) | Human leukocyte interferon composition | |
CN106177900A (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
US5977176A (en) | Compositions for the treatment of warts and herpes | |
JP2988937B2 (en) | Novel antitumor and antiviral compositions from marine sources | |
CN116808105B (en) | Preparation method and application of composition for preventing and treating male balanitis, dermatitis-wrapping, scrotitis and other reproductive inflammations | |
DE69120529T2 (en) | SUPPORTIVE USE OF LINOMIDE (R) | |
EP0815253B1 (en) | Multi-factor immunity modulator mixture, process for its production and medicaments containing said modulators | |
KR102258890B1 (en) | Composition for treating Graft Versus Host Disease comprising clonal stem cell | |
DE3236298C2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990416 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IE IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20010530 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 35/54 A, 7A 61K 35/60 B, 7A 61K 35/64 B, 7A 61P 35/00 B |
|
RTI1 | Title (correction) |
Free format text: PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYONIC EXTRACT AS AN ACTIVE SUBSTANCE AND RELATIVE PREPARATION PROCESS |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB IE IT LI NL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020821 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020821 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020821 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020821 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020821 |
|
REF | Corresponds to: |
Ref document number: 222499 Country of ref document: AT Date of ref document: 20020915 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69714856 Country of ref document: DE Date of ref document: 20020926 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2181004 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030612 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030612 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030522 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20030612 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050612 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20101014 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20101001 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20101002 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100930 Year of fee payment: 14 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: IT Effective date: 20110616 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: IT Effective date: 20110616 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20120229 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69714856 Country of ref document: DE Effective date: 20120103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110630 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120103 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130417 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110613 |